within Pharmacolibrary.Drugs.ATC.C;

model C09AA15
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 5.555555555555555e-06,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,
    adminCount     = 1,
    Vd             = 0.096,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 10.001999999999999
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>ATC code:</td><td>C09AA15</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Zofenopril is an angiotensin-converting enzyme (ACE) inhibitor used for treatment of hypertension and heart failure. It is a prodrug hydrolyzed to its active form, zofenoprilat. Zofenopril has been approved for clinical use in several countries, primarily in Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following a single oral dose.</p><h4>References</h4><ol><li><p>Chen, BL, et al., &amp; Zhang, W (2015). Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. <i>Therapeutics and clinical risk management</i> 11 309â€“318. DOI:<a href=\"https://doi.org/10.2147/TCRM.S64288\">10.2147/TCRM.S64288</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25750535/\">https://pubmed.ncbi.nlm.nih.gov/25750535</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>"
  ));
end C09AA15;
